JUN ROSE ABELLA: Open Payments
NPI 1396104147 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$386 in 14 payments from 8 companies in 2025. Trend: 2023 $125 · 2024 $274 · 2025 $386
Food & beverage: $386
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 4 | $123 |
| Merck Sharp & Dohme LLC | 4 | $96 |
| Baxter Healthcare | 1 | $48 |
| AstraZeneca Pharmaceuticals LP | 1 | $26 |
| Eisai Inc. | 1 | $25 |
| Solventum Corporation | 1 | $24 |
| Abbott Laboratories | 1 | $24 |
| ABBVIE INC. | 1 | $19 |
Products named: JEMPERLI, KEYTRUDA, PERCLOT, LYNPARZA, Lenvima, ACTIV.A.C., NAVITOR, ELAHERE.
Industry payments across NY — which companies pay providers there.
